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Abstract
Immune checkpoint factors, such as programmed cell death protein-1/2 (PD-1, PD-2) or cytotoxic T lymphocyte-
associated antigen-4 (CTLA-4) receptors, are targets for monoclonal antibodies (MAbs) developed for cancer
immunotherapy. Indeed, modulating immune inhibitory pathways has been considered an important breakthrough
in cancer treatment. Although immune checkpoint blockade therapy used to treat malignant diseases has provided
promising results, both solid and haematological malignancies develop mechanisms that enable themselves to
evade the host immune system. To overcome some major limitations and ensure safety in patients, recent
strategies have shown that combining epigenetic modulators, such as inhibitors of histone deacetylases (HDACi) or
DNA methyltransferases (DNMTi), with immunotherapeutics can be useful. Preclinical data generated using mouse
models strongly support the feasibility and effectiveness of the proposed approaches. Indeed, co-treatment with
pan- or class I-selective HDACi or DNMTi improved beneficial outcomes in both in vitro and in vivo studies. Based
on the evidence of a pivotal role for HDACi and DNMTi in modulating various components belonging to the
immune system, recent clinical trials have shown that both HDACi and DNMTi strongly augmented response to
anti-PD-1 immunotherapy in different tumour types. This review describes the current strategies to increase
immunotherapy responses, the effects of HDACi and DNMTi on immune modulation, and the advantages of
combinatorial therapy over single-drug treatment.
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Background
Accumulation of genetic alterations might be caused by
abnormal expression of genes that play a key role in
regulation of cell survival, proliferation, and death. In
addition, many studies have evaluated the capability of
epigenetic regulators to modulate gene expression in
cancer cells through covalent modification of DNA as
well as histone and non-histone proteins [1]. The most
important epigenetic processes reported in the clinical
settings involve DNA methylation and histone modi-
fications without altering the DNA sequence of bases.
DNA methyltransferases (DNMTs) catalyse the methy-
lation at cytosine-C5 mainly in a CpG dinucleotide
context at the promoters of selected genes [2]. Although
DNA methylation is essential for fundamental processes
like embryonic development or differentiation, aberrant
expression and/or activities of DNMTs are involved in
several pathologies, from neurodegeneration to cancer
[3–6]. DNMT enzymes are classified into three distinct
families: DNMT1; DNMT2, also known as TRDMT1
(t-RNA cytosine-5-methyltransferase); and DNMT3 (con-
sisting of DNMT3a, DNMT3b, and DNMT3L) [2, 7].
Currently, two DNMT inhibitors (DNMTi), the nuc-
leoside analogues azacitydine (5-AZA) and decitabine
(5-AZA-CdR), have been approved by FDA and the
European Medicines Agency (EMA) against myelodysplas-
tic syndromes (MDS), acute myeloid leukaemia (AML),
and chronic myelomonocytic leukaemia (CMML). DNMT
overexpression is described in numerous cancer types.
DNMTi can arrest tumour growth and cell invasiveness
and can induce cell differentiation [8]. Among histone-
modifying enzymes, histone acetyltransferases (HATs) and
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histone deacetylases (HDACs) are among the most studied
targets for chromatin remodelling, control of gene expres-
sion, and anticancer therapy. HDACs are divided into four
groups: “classical HDACs” are expressed in the nucleus
and/or cytoplasm, share a Zn2+-dependent catalytic activity,
and include class I (HDAC1, 2, 3, 8), IIa (HDAC4, 5, 7, 9),
IIb (HDAC6 and 10), and IV (HDAC11) enzymes. Class III
HDACs, known as sirtuins, possess NAD+-dependent dea-
cetylase activity and share no sequence similarity with the
classical deacetylases [9]. HDAC inhibitors (HDACi) can
induce, among others, tumour cell apoptosis, growth arrest,
differentiation, inhibition of angiogenesis, and immunogen-
icity [10]. Among them, vorinostat and romidepsin have
been approved for treatment of refractory cutaneous T cell
lymphoma (CTCL), belinostat and chidamide (the latter
approved only in China) for peripheral T cell lymphoma
(PTCL), and panobinostat for multiple myeloma (MM), all
from 2006 to 2015. Interestingly, most HDACi and DNMTi
have shown a potent immunomodulatory activity, thus
justifying their application in cancer immunotherapies. In
fact, there is a growing interest in understanding how these
potential therapies can modulate the host immune system
in order to achieve beneficial antitumour effects [11]. The
cancer immunotherapy field is under intense investigation
to ameliorate cancer cell recognition by immune cells and
to make them more sensitive to cytotoxic antitumour treat-
ment. Cancer immunotherapy refers to a diverse range of
therapeutic approaches to improve the capability of T cells
and other immune effector cells in recognition and elimin-
ation of cancer cells through overcoming of cancer cell
resistance in different tumour types [12]. Moreover, cancer
cell immune recognition provides the tools to modulate im-
mune signalling pathways that drive tumour growth and
progression, suggesting rational combinatorial approaches
[13]. This review will also focus on current immunomodu-
latory combinatorial treatment strategies aiming to improve
the effectiveness of cancer immunotherapy.
Cancer cell escape mechanisms and the role of
the immune system
Actually, cancer immunotherapy strategies designed to
break the immune tolerance can be broadly classified on
the basis of the mechanisms involved in resistance pro-
cesses. Such strategies include several factors: (i) adop-
tive transfer of immune effectors, (ii) vaccination, and
(iii) immunomodulatory therapy. In particular, effector
cells of innate immunity, such as natural killer (NK) cells
and macrophages, and adaptive immunity (such as T and
B cells) can eliminate immunogenic malignant cells [14].
Nevertheless, the main escape pathways, including anti-
apoptotic signalling, mitogen-activated protein kinase
(MAPK) pathway, microphthalmia-associated transcription
factor (MITF), cyclic adenosyl monophosphate (cAMP),
and nuclear factor kappa light chain enhancer of activated
B cells (NF-κB)-related mechanisms, negatively influence
the therapeutic success. Part of this failure is due to im-
mune suppression by the tumour microenvironment
(TME). So far, defective antigen presentation, tumour-
induced inhibitory checkpoint pathways against effector T
cell activity, infiltrating regulatory T cells (Tregs), myeloid-
derived suppressor cells (MDSCs), and secretion of im-
munosuppressive cytokines, such as transforming growth
factor β (TGF-β), interleukin-6 (IL-6), and vascular endo-
thelial growth factor (VEGF), represent the major mecha-
nisms for escaping [15]. It is well known that the immune
system protects the host against tumour development on
one side and promotes tumour growth by selecting tu-
mours of lower immunogenicity on the other side. These
two effects create a dynamic process also called “can-
cer immunoediting” that includes three phases: elim-
ination, equilibrium, and escape [16]. However, due to
their heterogeneity, tumour cells with a less immuno-
genic phenotype are able to escape this elimination
phase also called immunosurveillance and to expand
during the equilibrium phase. These considerations
have encouraged many researchers to develop new
therapeutic strategies to fight different cancer types
with immunotherapy.
Rationale for the development of cancer
immunotherapy strategies
Active research in tumour immunology includes studies
on adoptive T cell therapy and cancer vaccination, as
well as clinical investigation regarding immune check-
point blockade in combination therapy.
The immune system plays a key role in maintaining
self-tolerance and regulating T cell responses. For this
reason, it is very important to understand the complex
and dynamic nature of host immune responses and the
regulation of additional molecules in the TME in order
to develop strategies to improve clinical efficacy. Activa-
tion of antigen-specific T cells is a key step in immune
responses, and it is provided by the interaction between
the peptide-major histocompatibility complex (MHC)
complex and the T cell receptor (TCR) in the presence
of other co-stimulatory molecules. Among these mole-
cules, cluster of differentiation 28 (CD28), expressed on
the surface of naive CD4+ and CD8+ cells, is one of the
most important proteins involved in the initial activation
of the immune system response.
Conversely, the interaction between molecule and anti-
genic peptide in the absence of co-stimulation results in T
cell “anergy” instead of activation [17]. Immune system
homeostasis includes the presence of both stimulatory
and inhibitory signals such as cytotoxic T lymphocyte-
associated antigen-4 (CTLA-4, a CD28 homolog),
which acts by a competitive mechanism with CD28
for binding to its cognate ligands such as CD80/86
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expressed on the surface of antigen-presenting cells
(APCs) [18]. Another important immune checkpoint is
mediated by programmed cell death protein-1 (PD-1). In
comparison with CTLA-4, PD-1 regulates immune activ-
ity when effector T cell tissue infiltration occurs. Besides
activated T cells, PD-1 is mainly expressed on the surface
of activated B cells, NK cells, dendritic cells (DCs), and
Tregs [13]. Engagement of PD-1 by its ligands, either
PD-L1 or PD-L2, induces a negative control signal
resulting in the inhibition of T cell proliferation, cyto-
kine production, and cytotoxic activity [19]. Moreover,
upregulation of PD-L1 on different tumour types and
production of cytokines as a consequence of inflam-
matory signals induces an innate (tumour cell intrinsic)
and an adaptive resistance, respectively. Preclinical
studies have demonstrated that blocking the PD-L1/
PD-1 interaction augments antitumour T cell responses
[20]. About 20% of advanced non-small cell lung cancer
(NSCLC) patients and 30–40% of advanced melanoma
patients have provided tumour responses to PD-1
blockade monotherapy [21]. Therefore, modulation of
immune inhibitory pathways is considered as an im-
portant breakthrough in cancer treatment. In particular,
since 2011 with the approval by FDA of the monoclonal
antibody (MAb) ipilimumab for advanced melanoma,
and 3 years later of pembrolizumab and nivolumab as
well, there has been an increasing interest in this field.
Notably, ipilimumab, targeting CTLA-4 on T cells, al-
lows T cell activation for immune responses in several
cancers as well as inhibition of Treg function [22]. Early
clinical trials evaluated ipilimumab in patients with a
variety of malignancies, including melanoma, prostate
cancer, renal cell carcinoma, and non-Hodgkin lymph-
oma [23, 24]. Similarly, an intense investigation has
been conducted for nivolumab and pembrolizumab,
fully human and humanized IgG4 anti-PD-1 MAbs, re-
spectively [25, 26]. In general, different tumour type re-
sponses to checkpoint blockade are more closely
associated with inherent immunogenicity (mutational
burden or dominant neoantigens) than with the tumour
tissue origin [27]. In preclinical models, combined blockade
of PD-1 and CTLA-4 achieved more pronounced an-
titumour activity than blockade of either pathway alone
[28–31]. Indeed, the first reported ipilimumab and nivolu-
mab combination with response in melanoma has provided
a rationale for the development of immune checkpoint
combination strategies (NCT01024231) [32]. Additionally,
recent studies have shown a synergistic antitumour activity
in mouse MC38 and CT26 colorectal tumour models with
concurrent, but not sequential, CTLA-4 and PD-1 blockade
(ipilimumab and nivolumab) [33]. Updated reviews about
the current status of immunotherapy and clinical develop-
ments of immune checkpoint inhibitors have been recently
reported [34–36].
Epigenetic regulation of the immune system
Immune checkpoint regulation mechanisms include co-
valent modifications, microRNAs (miRNAs), long non-
coding RNAs (lncRNAs), and histone modifications [37].
Epigenetic modifiers can either turn on or turn off im-
mune responses, resulting in immune evasion [38]. Since
some epigenetic regulators have shown a potent immu-
nomodulatory activity, their combination with immune
checkpoint inhibitors could represent a promising thera-
peutic strategy. Currently, many researchers are investi-
gating the link between epigenetic modulation of the
immune system and cancer development. Among the
epigenetic processes implicated in immune regulation,
DNA methylation and histone acetylation are likely the
most important modifications in controlling development,
differentiation, and functions of T cells [39]. During im-
mune responses, naive CD4+ T cells differentiate into
several T helper (Th) cell subsets, including Th1, Th2,
Th17, and induced regulatory T (iTreg) cells, as defined
by their pattern of cytokine production [40]. Moreover,
CD4+ Th subsets are distinguished by their phenotype as
well as by the transcription factors that control their
differentiation, including T-bet in Th1, GATA-3 in Th2,
RAR-related orphan receptor γ (RORγT) in Th17, and
forkhead box protein 3 (Foxp3) in Treg [41]. The first
studies in humans showed that Th1 and Th2 cells are true
lineages regulated by epigenetic modifications occurring
on interferon-γ (IFN-γ), IL-4, and IL-13 genes. The IFN-γ
promoter is hypermethylated in human naive T cells and
is demethylated during the differentiation to Th1 cells
[42]. Conversely, Th2 cell differentiation results in the
selective demethylation of several specific CpG dinucleo-
tides in the IL-4 and IL-13 genes, which are expressed in
activated Th2 but not Th1 cells [43]. Moreover, epigenetic
histone marks are also essential for the Th1/Th2 cell fate
decisions. Signal transducer and activator of transcription
4 (STAT4) and T-bet or STAT6 and GATA-3 are key tran-
scription factors for the Th1 and Th2 lineages, respectively
[44]. The histone methyltransferase (HMT) SUV39H1,
which is involved in H3K9 trimethylation (H3K9me3), has
recently been implicated in the silencing of the Th1 locus
and the subsequent promotion of stability of Th2 cells
[45]. Chang et al. explored the mechanisms establishing
long-range H4 acetylation marks at the IFN-γ locus, dur-
ing Th1 lineage commitment. T-bet displaced the Sin3
transcription regulator family member A (Sin3A)-histone
deacetylase (HDAC1, HDAC2) complexes, to facilitate the
differentiation of Th1 cells [46]. In response to IL-12 sig-
nals, the activation of STAT4 required for the develop-
ment of Th1 cells facilitates chromatin remodelling at the
enhancer regions of Th1 genes. Similarly, Th2 commit-
ment requires STAT6 and GATA-3 activities in response
to IL-4 stimulation [47]. Therefore, transcription factors
not only promote T cell differentiation but also influence
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epigenetic states and gene expression programs that de-
fine a particular lineage. Furthermore, epigenetic histone
modifications by enhancer of zeste homolog 2 (EZH2), a
member of polycomb repressive complex 2 (PRC2), regu-
late differentiation and plasticity of CD4+ T cells. Notably,
EZH2 directly binds and facilitates correct expression of
T-box transcription factor 21 (Tbx21) and GATA-3 for
differentiating Th1 and Th2 cells, accompanied by in-
creased H3K27 trimethylation (H3K27me3) [48]. Finally,
in Tregs, Foxp3 is acting predominantly as a transcrip-
tional repressor and is required for establishment of the
chromatin repressive mark H3K27me3 in activated Tregs.
Indeed, Foxp3 has been found to interact with EZH2
exclusively in activated Tregs, suggesting that Foxp3
recruits the PRC2 complex to target genes and forms
repressive chromatin under inflammatory conditions [49].
Morinobu et al. analysed the histone acetylation levels of
Th1 genes, IFN-γ, T-bet, and IL18RAP in response to
different cytokines [50]. Multiple levels of regulation of
IFN-γ histone acetylation may reflect critical checkpoints
for Th1 differentiation. In addition, basic leucine zipper
transcription factor (BATF) regulates Th1 gene expression
via acetylation of T-bet and IFN-γ, considered as an im-
portant checkpoint in T cell differentiation [51]. Several
other findings suggest that miRNA epigenetic modifica-
tions in cancer can promote an immune evasion [52].
More recently, Cortez et al. have identified a novel mech-
anism of PD-L1 epigenetic regulation by which tumour
immune evasion is regulated by the p53/miR-34/PD-L1
axis [53]. Indeed, p53 influences immune response by
monitoring T cell activation and inflammatory cytokines
and enhancing tumour cell recognition by NK cells [54,
55]. Furthermore, the overexpression of T cell immuno-
globulin and mucin domain 3 (Tim-3) on T cells ne-
gatively controls the antitumour T cell responses, with
important implications for anti-PD1 immunotherapy [56].
Another important immune checkpoint is lymphocyte-
activation gene 3 (LAG-3), highly expressed on activated
T cells in many cancer types, that can be used as an im-
munotherapy target [57]. miR-138 has been reported with
a multifaceted role in carcinomas, although its ability to
interact with the immune system is unknown. Wei et al.
have demonstrated that the combination of miR-138 with
a MAb therapy against CTLA-4 provided a strong thera-
peutic synergism. Transfection of human CD4+ T cells
with miR-138 suppressed expression of CTLA-4, PD-1,
and Foxp3 in glioma preclinical models [58]. Moreover,
previous studies described a novel biological role of other
miRNAs in regulating the expression of immune check-
points [59, 60]. Hence, targeting these miRNAs in com-
bination with traditional immune checkpoint inhibitors is
certainly a potent immunotherapeutic strategy. At last,
lncRNAs are also critical mediators in various tumours
associated with cancer progression [61, 62]. Notably,
Zeng et al. have found that the nuclear paraspeckle
assembly transcript 1 (NEAT1) expression was repressed
by PML-RARα, a leukemic-specific antigen and part of
the PD-1 pathway. Moreover, reduced NEAT1 expression
may play a role in the myeloid differentiation of acute pro-
myelocytic leukaemia (APL) cells [63]. Many lncRNAs are
bound and regulated by the key T cell transcription factors
T-bet, GATA-3, STAT4, and STAT6. Hu et al. have found
that LincR-Ccr2-5′AS, together with GATA-3, is essential
for regulation of several chemokine receptor genes and for
Th2 cell migration, but the exact mechanism of action of
LincR-Ccr2-5′AS is currently unknown [64].
The potential role of epi-drugs as “immune-
regulators”
HDACi are being used as a novel, therapeutic approach
for treatment of leukaemia and other haematological
malignancies [2, 65]. However, their effect on immune
cells remains ill-defined, as HDACi may impair immune
surveillance. Cancer arises as a result of accumulation of
genetic mutations and epigenetic aberrations regulated
by many players including HDACs. Abnormal expres-
sion of HDACs has been reported in tumours, whereas
knockdown of HDACs inhibits tumour growth [66].
Tumour cell-intrinsic responses to HDACi treatment
involving cell death, arrest of proliferation, and modula-
tion of tumour immunogenicity have already been well
described and reviewed [2, 67]. In particular, cell death
is one of the deepest studied antitumour activity of
HDACi, which are able to induce apoptosis by various
pathways and processes, including activation of both in-
trinsic and extrinsic apoptosis pathways by modulating
expression of pro- and anti-apoptotic genes, and by acti-
vating and/or inducing transcription factors such as
E2F1, forkhead box protein O1 (FOXO1), p53, and spe-
cificity protein 1 (Sp1) [68, 69]. Another important
mechanism by which HDACi can induce tumour cell
death is the generation of reactive oxygen species (ROS)
that decrease the expression of free radical scavengers. It
has been reported that vorinostat and entinostat treat-
ment can induce selective accumulation of ROS and
caspase activation only in transformed cells [70]. Hui et
al. have demonstrated that synergistic killing of gastric
carcinoma (GC) cells by bortezomib/romidepsin com-
bination was dependent on ROS generation and caspase
activation. Collectively, this combinatorial effect could
also induce autophagy by the activation of MAPK family
members (ERK1/2 and JNK) [71]. Furthermore, a syn-
ergistic antiproliferative effect has been observed by
combination treatment with vorinostat and gefitinib or
erlotinib, two epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitors (TKIs), through reduction of cell
migration in NSCLC cells. However, the key finding of this
study is that the upregulation of the major mitochondrial
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porin, the voltage-dependent anion-selective channel pro-
tein 1 (VDAC1), by vorinostat and TKIs could be involved
in oxidative stress-dependent apoptosis. In addition, the
usage of vorinostat alone or in combination modulated
the c-Myc-NRF2-KEAP1 pathway, crucial for the redox
stress response [72]. Further important biological re-
sponses to HDACi include cell cycle arrest at the G1/S
and G2/M checkpoints, cellular senescence, and au-
tophagy. A recent study has shown that activation of
FOXO1 transcription factor by HDACi is an important
mediator of autophagic response [73]. HDACi have been
recently tested in combination with immunotherapeutic
approaches. In addition to their direct antitumour effects,
these agents could facilitate recognition and sensitivity to
effector functions by cytotoxic T lymphocytes (CTLs) and
NK cells, thereby sensitizing cancer cells to immunot-
herapy. Conversely, in cancer patients, immunological side
effects of HDACi such as lymphopenia, leukopenia, neu-
tropenia, and thrombocytopenia might be contradictory
for their application in cancer immunotherapy. On the
other hand, there is an increasing number of studies
showing beneficial effects and immunomodulatory pro-
perties of these agents. To date, a number of studies
referring to the ability of HDACi in upregulating MHC,
co-stimulatory molecule expression, components involved
in tumour necrosis factor (TNF) superfamily signalling
have been performed [74]. Nevertheless, the molecular
mechanisms underlying the involvement of HDACi-
regulated genes in immune recognition are not fully
understood. Trichostatin A (TSA), a pan-HDACi, in com-
bination with valproic acid (VPA), a class I/IIa HDACi,
has been reported to enhance cell surface expression of
class I MHC and co-stimulatory molecules CD40 and
CD86 in melanoma cells [75]. In the same way, sodium
butyrate, a class I/IIa HDACi, and TSA activated expression
of class I and II MHC and CD40 in multiple human neuro-
blastoma (NB) or mouse plasmacytoma J558 tumour cell
lines [76]. Furthermore, romidepsin promotes tumour-
specific T cell-mediated killing of B16/F10 murine melan-
oma cells and enhances the expression of class II MHC,
CD40, and B7-1/2 [77]. Many studies reported that HDACi
sensitize tumour cells to NK cell lysis by promoting expres-
sion of NK cell ligands [78–80]. Moreover, low cell cytotox-
icity by reducing the NK cell activation receptors has been
documented using therapeutic concentration of vorinostat
and VPA. In a further study, Rossi et al. have demonstrated
the reduction of NK cell production by IFN-γ after TSA,
VPA, and sodium butyrate treatment [81]. HDACi are also
important for macrophage differentiation, polarization, and
innate defence function [82]. Multiple studies showed a
suppressive role of HDAC inhibition during macrophage
activation status. Roger et al. have described that the block-
age of class I and II HDACs enhances the recruitment of
the repressive complex Mi-2b to the promoters of M1
activation state genes, such as II6 [83]. Cabanel et al. have
highlighted the role of TSA as a macrophage differentiation
and elongation regulator. They assessed, for the first time,
that macrophage plasticity is kept by HDAC inhibition. Fur-
thermore, simultaneous inhibition of class I and II HDACs
in several macrophage populations results in reduced levels
of recognition receptors, activation markers, cytokines, and
chemokines [84]. Moreover, HDAC inhibition can func-
tionally target Tregs and helps to break the immune toler-
ance. Low levels of Tregs exist under normal physiological
conditions, where they mediate the suppression of sus-
tained inflammation, prevent autoimmune responses, and
keep homeostasis of immune response. In cancer patients,
Tregs are induced by tumour or stroma-secreted factors
and also regulated by effector B, T cells, and OX40/OX40L
expressed on activated CD4+ and CD8+ T cells, members
of the TNFR/TNF superfamily [85, 86]. Tregs are capable
of inhibiting NK and T cell function in TME, thus impair-
ing both innate and tumour antigen-specific antitumour
immune responses. Nowadays, it is well established that
Foxp3 is the major key regulator of Treg development and
function. Among the epigenetic modifications, acetylation,
together with methylation, regulates the stability and activ-
ity of Foxp3 [87]. Furthermore, recent reports have de-
scribed opposite mechanisms by which different HDAC
isoforms modulate Treg and Treg-Foxp3 expression. For
instance, by enhancing Foxp3 acetylation, entinostat has
been found to increase Treg suppression function. The
mechanism of Foxp3 expression regulation by entinostat
may involve acetylation of STAT3 protein, which is a sub-
strate of HDAC3 [88]. Conversely, other authors have
shown Treg and Foxp3 downregulation following en-
tinostat treatment [89]. Beier et al. suggested that Sirt1,
HDAC6, or HDAC9 have different effects on Treg biology.
Although HDAC inhibition increased the expression of the
Foxp3-encoding gene, the transcription factors involved are
different. In particular, loss of HDAC9 stabilizes STAT5
acetylation (K694, K701, and K359) and phosphorylation
(Y694) and increases Treg function [90]. On the contrary,
HDAC5 decreased Treg suppressive function and impairs
iTreg formation as well as IFN-γ production [91]. Other
researchers have investigated the effect of HDACi on
suppressive myeloid cells, including myeloid-derived sup-
pressor cells (MDSCs) that are comprised of monocytic
(M-MDSC) and polymorphonuclear (PMN-MDSC)
cells. Suppressive myeloid cells, also including tumour-
associated macrophages (TAMs), are induced by tumour
growth and accumulated in TME. These cells impair host
immunity against tumour cells and facilitate tumour pro-
gression and metastasis. Youn et al. have reported that
HDAC2 inhibitors can directly interact with the retino-
blastoma 1 (Rb1) promoter and participate in silencing
Rb1 expression in tumour-bearing hosts. This evidence
suggested that HDAC2 inhibitors may regulate pathologic
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differentiation of myeloid cells in cancer [92]. It has been
shown that treatment with TSA and vorinostat led to the
expansion of MDSCs in bone marrow cells in vitro, and
this effect has been confirmed also in vivo by TSA treat-
ment [93]. Recently, to deeply explore the HDACi impact
on antigen presentation, Tiper and Webb have provided
evidence on combination of HDACi and NK T cell-based
immunotherapy. Importantly, HDACi treatment not only
enhances both CD1d- and class II MHC-mediated antigen
presentation but also inhibits inflammatory cytokine se-
cretion, which may contribute to the suppression of anti-
tumour NK T cell responses. Moreover, the same authors
demonstrated the efficacy of HDACi in restoring antitu-
mour responses to mantle cell lymphoma (MCL) through
both cell-intrinsic and cell-extrinsic mechanisms [94].
Also, DNMTi seem to be implicated in the modulation
of various immune system components, including tumour-
associated antigen (TAA) and antigen presentation machin-
ery (APM). Cancer testis antigens (CTAs) are a large family
of tumour-associated antigens expressed in histologically
different human tumours, but not in normal tissues except
for the testis and placenta. CTAs include the melanoma-
associated antigen (MAGE), NY-ESO-1, and SSX gene
families and the GAGE/PAGE/XAGE superfamilies, and
they are expressed by neoplastic cells and recognized by
CTLs. These tumour-restricted expression patterns, to-
gether with their strong in vivo immunogenicity, identified
CTAs as ideal targets for tumour-specific immunothera-
peutic approach, and several clinical trials for a CTA-based
vaccine therapy have been developed after these findings
[95–97]. DNA methylation can lead to induction or upreg-
ulation of CTA expression in histologically different solid
tumour cells, as well as in stem cells [98]. CTAs, such as
preferentially expressed antigen in melanoma (PRAME),
have been induced by pharmacological inhibition (5-AZA-
CdR) or genetic knockdown of DNMTs, in epithelial ovar-
ian cancer (EOC) or in HGSC [99]. DNMTi are capable of
regulating APM on tumour cells through different mecha-
nisms. APM plays an important role during the recognition
phase and lysis of neoplastic cells by antigen-specific CTLs
and represents a good candidate for immunotherapy
likewise CTAs. In addition, to boost immune response,
DNMTi can decrease immunosuppression by reducing
Treg function [100]. Interestingly, DNMTi and HDACi
were strongly effective in inducing upregulation of APM
component expression in a broad spectrum of tumour
types, suggesting a contribution by indirect epigenetic
mechanisms not yet identified [101]. Recently, the role of
histone methyltransferases (HMTs) in tumour immunity
has been investigated. For instance, combination of EZH2
inhibitors such as deazaneplanocin A (DZNep) or tazeme-
tostat (EPZ6438) with 5-AZA displayed improved thera-
peutic efficacy of anti-PD-L1 treatment by increasing Teff
tumour infiltration and decreasing tumour progression
[102]. EZH2 and other PRC2 components have been found
to repress the expression of CXCL9 and CXCL10 (Th1-
type chemokines) even in colon cancer [103]. However,
initial support for the immunological efficacy of DNMTi,
alone or combined with HDACi, came out from studies in
haematological malignancies, such as AML and MDS, for
which 5-AZA and 5-AZA-CdR have been approved by
FDA, as already mentioned. In the last decade, a clinical
study has reported that the administration of 5-AZA-CdR
with VPA induces anti-MAGE CD8+ response in 50% of
patients with AML (Fig. 1) [104].
The structures of the epi-drugs discussed in the above
section are shown in Fig. 2.
Preclinical studies of HDACi and DNMTi in
combination with immunotherapies
In this section, main preclinical studies are described
involving immunotherapy strategies in combination with
HDACi or DNMTi (Fig. 2). As aforementioned, HDACi
can enhance T cell survival and function and induce
expression of multiple chemokines in tumour cells,
tumour-infiltrating macrophages, and T cells, thus aug-
menting the response to anti-PD-1 immunotherapy in
lung adenocarcinoma [105]. Over the last decade, exten-
sive studies have been carried out to evaluate the efficacy
of combining HDACi with various immunotherapy treat-
ments to overcome cancer cell resistance and strongly
improve clinical responses.
Recently, Kim et al. have reported that treatment with
both anti-PD-1 and anti-CTLA-4 antibodies was unable
to eradicate two types of immunogenic tumours, namely
CT26 and 4T1. Nevertheless, co-treatment with epi-
genetic modulating drugs and checkpoint inhibitors im-
proved treatment outcomes, curing more than 80% of
the tumour-bearing mice. In this study, animals bearing
large CT26 tumours (>600 mm3) were treated with anti-
PD-1 and anti-CTLA-4 antibodies, in combination with
5-AZA or entinostat. The resulting data showed the
eradication of primary tumours in 10 out of 11 mice.
Interestingly, the primary tumours and metastases were
not found in any of the mice treated with both anti-
bodies plus entinostat, whereas only the primary tumour
was detected in the mice treated with both antibodies
plus 5-AZA [106]. Preclinical studies suggest that HDAC
inhibition induces upregulation of PD-L1, and to a lesser
extent PD-L2, in a dose-dependent manner. These re-
sults have been obtained in vitro and further confirmed
in vivo using a murine B16F10 cell melanoma model.
Among the inhibitors evaluated, panobinostat displayed
the greatest ability to enhance PD-L1 expression, provid-
ing a rationale for panobinostat/anti-PD1 combinatorial
treatment [107]. Currently, a better understanding of the
molecular mechanisms by which HDACi elicit immu-
nostimulatory effects would contribute to their clinical
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development as anticancer agents. More recently, in
order to test whether HDACi could have a synergistic
effect with immunotherapy, panobinostat has been admin-
istered in an in vivo B16 melanoma model in combination
with T cell transfer therapy [108]. In this study, panobino-
stat improved the effectiveness of gp100-specific T cell im-
munotherapy and maintained systemic pro-inflammatory
levels. Moreover, it enhanced proliferation, retention, and
polyfunctional status of tumour-specific T cells, leading to
decreased tumour burden and highly decreased Treg pop-
ulations. Kroesen et al. have shown that combination of
anti-GD2 plus vorinostat reduces NB tumour growth
[109]. Further studies have also shown that HDACi up-
regulate the expression of various components of the
immune system, in particular molecules involved in APM
as well as those involved in immune co-stimulation.
Horing et al. described how TSA, in addition to induc-
tion of apoptosis in tumour cells, can augment anti-
glioblastoma multiforme (GBM) innate immune responses.
Systemic treatment with TSA delayed GBM xenograft
growth by enhancing tumour recognition by NK cells
[110]. As already aforementioned, HDACi may regulate
APM through different ways including activation of class II
transactivator (CIITA), a master regulator of MHC II [111].
Additionally, it has been demonstrated that entinostat
increased the level of MHC II by transcriptional activation
of CIITA in diffuse large B cell lymphoma (DLBCL) [112].
Furthermore, NB and hepatoma cells treated with VPA
have shown increased sensitivity to NK cell killing through
transcription of MHC class I-related chain A and B (MICA
and MICB). In addition, VPA at non-toxic pharmacological
concentration arrested growth, induced differentiation, and
increased immunogenicity of NB cells through non-toxic
mechanisms [113]. Further experiments have been carried
out to evaluate the effect of vorinostat on regulation of
MICA/B expression. In this study, Yang et al. have reported
that vorinostat upregulates the transcription of MICA/B by
promoting MICA-associated histone acetylation and by
suppressing the MICA/B-targeting miRNAs, such as miR-
20a, miR-93, and miR-106b. Vorinostat can regulate miR-
17-92 cluster and MCM7 to upregulate MICA expression
in hepatoma [114].
Romidepsin displayed an antiproliferative effect on T
cells by inhibition of the production of IL-2 and down-
regulation of CD25 (part of the IL-2 receptor) [115].
Although poor efficacy was observed in the antitumour
immune response in vivo, Cao et al. have demonstrated
that in vivo treatment with TSA induced suppression of
nuclear factor of activated T cells 1 (NFAT1)-regulated
FasL expression on activated CD4+ T cells. Importantly,
they also found that the co-administration of HDACi
and anti-CTLA-4 could further enhance the infiltration of
CD4+ T cells and achieve a synergistic anticancer effect. In
fact, within this study, modulation of activation-induced
Fig. 1 Interaction between tumour and immune cells. T cell stimulation is driven by antigens and requires a coordinated participation of several other
receptors and molecules expressed on the T cell surface and antigen-presenting cells (APCs) or tumour cells. HDACi and/or DNMTi can inhibit different
signalling pathways involved in adaptive immune responses, enhancing antitumour effects by combination with immune checkpoint inhibitors
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cell death (AICD) of tumour-infiltrating CD4+ T cells by
TSA enhanced antitumour immune responses, uncovering
a novel mechanism underlying the antitumour effect of
HDACi [116]. Previous studies have evaluated the capabil-
ity of rocilinostat (ACY-1215), a HDAC6-specific inhibitor,
to prevent skin inflammation through blocking the ef-
fector CD8+ T cells and impairing the MAPK pathway
[117]. Furthermore, since tumour growth induces accu-
mulation of immunosuppressive cells including Tregs, a
huge number of studies addressing the effect of HDACi
on Tregs and other immunosuppressive cells have been
performed. Entinostat inhibited Foxp3 expression and
Treg suppressive function in a dose-dependent manner
and, at lower doses, enhanced cytokine and vaccine ther-
apies in murine renal cell carcinoma and prostate cancer
models, respectively [88]. In contrast, in murine colitis
models of inflammation and autoimmunity, the HDAC6-
selective inhibitors tubacin and tubastatin A enhanced
Treg suppressive function [118]. More studies have re-
vealed that co-treatment with HDACi or DNMTi and
checkpoint inhibitors were capable of suppressing MDSCs
and eradicate metastatic mouse cancer resistant to im-
mune checkpoint blockade [106]. A very recent study has
demonstrated that prostate (LNCAP) and breast (MDA-
MB-231) carcinoma cells are more sensitive to T cell-
mediated lysis in vitro after clinically relevant exposure to
epigenetic therapy with either vorinostat or entinostat and
that genetic or pharmacological inhibition studies identi-
fied HDAC1 as a key determinant to reverse carcinoma
immune escape [119]. Moreover, in two non-epithelial
cancers (glioma and mesothelioma), it was found that the
epigenetic regulation of the NY-ESO1 gene requires the
sequential recruitment of the HDAC1-mSin3a-NCOR and
DNMT1-PCNA-UHRF1-G9a complexes [120].
Treatment with DNMTi allows immunological recogni-
tion and cytolysis of cancer cells overcoming the resistance
Fig. 2 Structures of epi-drugs discussed in this review
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to CTA-specific CTLs. 5-AZA-CdR has been reported to
modulate the expression of both CTA and class I human
leucocyte antigen (HLA) and the resulting modification in
neoplastic cell immunogenicity [121]. 5-AZA has been
shown to upregulate PD-L1 in EOC and NSCLC cell lines,
eliciting the activation of the viral/IFN response [122].
Nevertheless, another recent report has shown that PD-1
promoter demethylation was associated with PD-1 mRNA
upregulation and worse overall response in MDS patients
[123]. Notably, patients with MDS resistant to DNMTi
showed elevated levels of PD-L1, PD-L2, and CTLA-4,
suggesting a putative involvement of PD-1 signalling in
resistance mechanisms to hypomethylating agents [124].
Importantly, Odunsi et al. performed a phase I dose escal-
ation of 5-AZA-CdR, in addition to NY-ESO-1 vaccine and
doxorubicin liposome chemotherapy, in 12 patients with
relapsed EOC. Increased NY-ESO-1 serum antibodies and
T cell responses were observed in most patients, encour-
aging further evaluation in other tumour types [125].
Based on the evidence above highlighted, the cooperation
between DNA methylation and histone acetylation in con-
trolling gene transcription prompted some researchers to
explore new combined therapies using both HDACi and
DNMTi. A synergistic upregulation of MAGE-A genes in
selected cancer cell lines by 5-AZA-CdR/TSA combination
has been reported [126]. Despite these results, a non-
durable synergistic effect was observed for such a combin-
ation, with DNMTi remaining the most effective epigenetic
drugs in modulating CTA expression in cancer cells.
Additional preclinical data confirmed the upregulation of
cellular CTA expression by systemic administration of 5-
AZA-CdR and modification of class I HLA antigen expres-
sion [127]. These in vivo modulations, including NY-ESO
expression, were still detectable on melanoma xenografts
30 days after the end of 5-AZA-CdR administration, and
injection of BALB/c mice generated high-titre anti-NY-
ESO-1 antibodies [127]. Furthermore, 5-AZA-CdR induced
demethylation of the Toll-like receptor 4 (TLR4) promoter,
an important modulator of the immune response in various
cancers, and increased H3K4 trimethylation and Sp1 bind-
ing to reactivate silenced TLR4.
In addition, it was demonstrated that the recruitment
of the MeCP2/HDAC1 repressor complex increased the
low levels of TLR4 expression through epigenetic modi-
fication of DNA and histones on the TLR4 promoter in
gastric cancer cells [128]. A phase I trial showed that 5-
AZA-CdR may be a potential modulator of the immune-
activating properties of high-dose IL-2 in melanoma and
renal cell carcinoma patients. While upregulation of
chemokines and genes involved in IL-1, IL-17, IL-22,
and IFN signalling might favour the activity of adminis-
tered IL-2, downregulation of IL-2Ra, CD3-ε, CD2, and
genes involved in IL-2 signalling can be expected to
impair IL-2 activity [129].
Clinical investigation of HDACi or DNMTi
treatment in combination with immunotherapies
In the light of the above considerations, researchers have
proposed the clinical use of some epigenetic drugs in
order to overcome some major limitations of current
therapeutic strategies to fight cancer and to evaluate their
efficacy and clinical tolerability. Many preclinical studies
have been conducted using different classes of HDACi,
also corroborated by an increasing number of clinical
investigations started by combining HDACi with immu-
notherapeutics. Immune evasion is the major obstacle to
the efficacy of cancer immunotherapies, by preventing
long-lasting tumour control. Hence, there is a strong need
to restore tumour immune recognition of malignant tu-
mours in order to increase the clinical benefit for patients.
HDACi appear to be able to improve the in vivo therapy
efficacy, and, although additional preclinical data are
needed to assess the efficacy and toxicity of these drugs
alone or in combination with other chemotherapeutics
and immunotherapy strategies, several clinical studies are
being investigated (Table 1). Among current clinical trials,
in patients with advanced renal or urothelial cell carcin-
oma, pembrolizumab and vorinostat will be administered
to evaluate the antitumour activity by estimation of
serious adverse events (AEs), maximum tolerated dose
(MTD), and progression-free survival (PFS). These clinical
studies have a run-in phase with sequential single agents
and then a combination phase. Thirty patients will be
enrolled in two expansion cohorts: 15 anti-PD1-naive pa-
tients and 15 anti-PD1-resistant patients (NCT02619253,
Table 1) [130]. More interesting evaluation of the potential
combined therapy targeting cancer cells will be repre-
sented by the study that keeps in consideration the possi-
bility to treat metastatic eye melanoma (PEMDAC) with
pembrolizumab and entinostat. Their co-administration
will be, respectively, intravenously (IV) for pembrolizumab
at 200 mg and orally for entinostat at 5 mg for a period of
24 months. PFS and clinical beneficial rate (CBR) are
some of the parameters that should be characterized to
evaluate patient responses (NCT02697630, Table 1) [130].
Focusing on DNMTi, 5-AZA or entinostat will be
orally administered to metastatic NSCLC patients to-
gether with the monoclonal anti-PD1 antibody nivolumab
(NCT01928576, Table 1) [130]. In a phase I study, the
safety of a combination between orally administered pem-
brolizumab and 5-AZA will be evaluated (NTC02546986,
Table 1) [130]. Likewise, in a phase II study, 60 patients
with NSCLC will be enrolled to evaluate the efficacy of 5-
AZA-CdR plus nivolumab treatment vs nivolumab alone
(NCT02664181, Table 1) [130]. An overview of all other
combinations is shown in Table 1.
Analysing the recent clinical trials, vorinostat and 5-
AZA are the drugs most frequently used, likely due to
their intense preclinical and clinical investigations.
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Conclusions
Robust data support the role of epigenetic drugs in
facilitating immunological targeting of cancer cells by
their ability to modulate different mediator factors and
pathways involved in the interaction between tumour
cells and the immune system. Following this observa-
tion, HDACi or DNMTi have been combined with
immune checkpoint therapies to provide more signifi-
cant benefit for cancer patients than monotherapy. In
this review, we have summarized preclinical and clinical
results combining HDACi or DNMTi with immune
checkpoint inhibitors and their direct effects on various
components of the immune system. Although more and
more preclinical trials are being conducted to enhance
safety and efficacy, especially for DNMTi, these findings
will help along the road for the discovery and the devel-
opment of novel therapeutic approaches in cancer im-
munotherapy. Focused on the results from preclinical
studies of HDACi on Tregs, either class I or class II
HDAC inhibition may have opposite effects on Treg
function as inhibition or promotion, respectively. Thus,
it is currently believed that cancer treatments with class
I-specific HDACi could provide future interesting out-
comes in patients. Indeed, different studies have shown
that immunomodulatory effects of HDAC inhibition
with high specificity may lead to a selective immune
regulation, when compared with pan-HDACi treatment.
Even if selective HDACi may provide greater efficacy,
the identification of the proper dose could reduce the
adverse effects associated with HDAC inhibition. Re-
gardless of which epigenetic modulator is used in
preclinical or clinical studies, the toxicity on different
tumours types remains a great challenge. A better un-
derstanding of the molecular mechanisms by which
HDACi and DNMTi elicit immunomodulatory effects
could help to ameliorate their clinical development.
Nevertheless, to achieve beneficial responses in patients,
a deep investigation on the main molecular processes on
which the immune system relies remains of high inter-
est. Future inquiry on immuneregulatory mechanisms
could provide more interesting targets for epigenetic
drugs in order to improve cancer cell recognition by T
cells and overcome cancer therapy failure. In addition,
it could be interesting to evaluate the immunomo-
dulatory activity of other epigenetic modulators (i.e.
HMTs and demethylase inhibitors), even highlighting
their clinical effects by combination with the already
described HDACi or DNMTi.
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